Novo Nordisk secures license to weight-loss drug candidate from China's United Labs
24/03/2025 10:19
March 24 (Reuters) - China-based United Laboratories International 3933.HK said on Monday it will license its weight-loss drug candidate to Danish drugmaker Novo Nordisk NOVOb.CO in a deal worth up to $2 billion. (Reporting by Mariam Sunny in Bengaluru; Editing by Shinjini Ganguli) ((Mariam.ESunny@thomsonreuters.com;))
Recent news on United Laboratories International Holdings
See all newsBrief: United Laboratories International Receives Milestone Payment From Novo
Brief: United Laboratories International Says NMPA Accepts Insulin Degludec And Liraglutide Injection Marketing Registration Application
Brief: United Laboratories International Posts HY Profit Attributable RMB 347.6 Million
China's United Laboratories half-year profit drops 82%
Brief: United Laboratories International Expects HY Net Profit RMB 340 Million